Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.62 |
| ▸ | PLAU | P00749 | 8/20 | 0.56 |
| ▸ | F9 | P00740 | 4/20 | 0.56 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807930 | 0.91 | F10 (0.60) | F10PRSS1PLAUF9F2 | |
| SCHEMBL6802349 | 0.81 | F9 (0.49) | F10PLAUF9 | |
| SCHEMBL6806834 | 0.81 | POLB (0.54) | F10PRSS1PLAUF9POLB | |
| SCHEMBL7114682 | 0.81 | F10 (0.68) | F10PRSS1PLAUF9F2 | |
| SCHEMBL5166349 | 0.80 | F10 (0.66) | F10PRSS1PLAUF9F2 | |
| SCHEMBL6807833 | 0.79 | F10 (0.73) | F10PRSS1F2PLG | |
| SCHEMBL7120375 | 0.79 | F10 (0.57) | F10PRSS1F2PLG | |
| SCHEMBL5165503 | 0.77 | F10 (0.70) | F10PRSS1PLAUF9F2 | |
| SCHEMBL5163692 | 0.77 | F10 (0.67) | F10PRSS1PLAUF9F2 | |
| SCHEMBL5163975 | 0.77 | F10 (0.65) | F10PRSS1PLAUF9F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | F10 64/4885PRSS1 1089/4885PLAU 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.